MELBOURNE, Australia and MONTREAL, June 25, 2018 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX:TLX) (“Telix Group”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals (“Isologic”).
Telix is developing 89Zr-girentuximab (TLX250) for the imaging of clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET). Telix has selected Isologic to manufacture TLX250 for the Company’s planned confirmatory Phase III clinical trial in North America and as a commercial partner for the Canadian market.
Dr. Bernard Lambert, President of Telix USA noted, “The agreement with Isologic delivers an important component of Telix’s manufacturing network in North America. We are delighted to initiate this partnership with Isologic, not only deliver material for clinical trials in the US but to also initiate commercial access for TLX250 in Canada. We selected Isologic for their experience in GMP manufacturing and comprehensive geographic coverage.”
Andre Gagnon, president of Isologic Innovative Radiopharmaceutical noted, “We are excited to partner with Telix for the production and distribution of such a potentially important radiopharmaceutical. Our collaboration with Telix will deliver an important new imaging technology to kidney cancer patients and we are pleased to be part of making the technology available in both the US and Canadian markets. This agreement is well aligned with our vision to help provide breakthrough radiopharmaceuticals to the marketplace.”
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix Group, Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
About Isologic Innovative Radiopharmaceuticals
ISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) is a Canadian radiopharmaceutical company dedicated to nuclear medicine and the science of radiopharmaceutical production. ISOLOGIC’s commitment to these fields includes cyclotron centers, SPECT and PET radiopharmaceutical manufacturing facilities throughout Canada. Utilizing significant experience, expertise to provide its customers and patients with reliable, safe and high quality radiopharmaceutical products and services. ISOLOGIC’s open formulary of radiopharmaceutical drugs and medical devices provides the flexibility of choice, providing its customers with access to all radiopharmaceuticals, having Health Canada market authorization.
Important Information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration or Health Canada.
CONTACT: Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com Telix Investor Relations (Australia) Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au Telix Investor Relations (US) Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: lwilson@insitecony.com
